Long-term treatment with growth hormone of children with short stature and normal growth hormone secretion.
Children with short stature but normal growth rate and/or normal growth hormone response to sleep and secretagogues were treated with recombinant methionyl human growth hormone, 0.3 mg/kg per week. In each year of treatment, about 80% of the subjects maintained an increase in growth rate greater than the defined limit (greater than 1 cm/yr above pretreatment growth rate) for continuation of human growth hormone treatment. Comparison of the group that continued to respond to human growth hormone with the group that did not maintain an accelerated growth rate did not reveal differences in bone age delay, sleep or secretagogue-stimulated human growth hormone secretion, degree of short stature either absolute or relative to target height, and somatomedin C concentration before or after initiation of therapy. The group that failed to respond to the human growth hormone treatment in the first year of treatment was younger and had a higher pretreatment growth rate. Review of the longitudinal growth curves revealed five patterns of response to human growth hormone treatment: (1) failure to increase growth rate in two subjects with height SD scores within 1 SD of target height, (2) failure to increase growth rate in five subjects with height SD scores greater than 1 SD less than the target height, (3) acceleration in growth rate in three subjects that was not maintained until achievement of a height within 1 SD of the target height, (4) acceleration of growth rate in five subjects that was maintained until achievement of a height within 1 SD of the target height, and (5) acceleration in growth rate that was maintained during the 3 years of treatment in 15 subjects who had not attained a height within 1 SD of the target height. We conclude that human growth hormone treatment of some but not all short children with "normal" growth hormone secretion will result in sustained acceleration of growth rate and attainment of prepubertal heights that are closer to but do not exceed their genetic height potential. A clinical trial of human growth hormone may be necessary to determine which subjects will benefit from the treatment.
Moore
W V
WV
Department of Pediatrics, University of Kansas Medical Center, Kansas City 66103.
Moore
K C
KC
Gifford
R
R
Hollowell
J G
JG
Donaldson
D L
DL
D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects* / Q000235:genetics; D002648:Child; D003000:Clonidine; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use; D019382:Human Growth Hormone; D006801:Humans; D007980:Levodopa; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012890:Sleep / Q000502:physiology; D013997:Time Factors
D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007980:Levodopa; D013006:Growth Hormone; D003000:Clonidine